Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
oncology (39) 39
index medicus (38) 38
humans (37) 37
female (36) 36
male (36) 36
aged (34) 34
chemotherapy (34) 34
middle aged (33) 33
cancer (28) 28
adult (22) 22
treatment outcome (17) 17
metastasis (16) 16
colorectal cancer (15) 15
stomach neoplasms - drug therapy (14) 14
antineoplastic combined chemotherapy protocols - therapeutic use (13) 13
patients (13) 13
aged, 80 and over (12) 12
cancer therapies (12) 12
cisplatin (12) 12
clinical trials (12) 12
gastric cancer (12) 12
medicine & public health (12) 12
research (12) 12
care and treatment (11) 11
drug combinations (11) 11
pharmacology & pharmacy (11) 11
survival (11) 11
trial (11) 11
tumors (11) 11
antimitotic agents (10) 10
antineoplastic agents (10) 10
colorectal neoplasms - drug therapy (10) 10
stomach cancer (10) 10
adenocarcinoma (9) 9
antineoplastic combined chemotherapy protocols - adverse effects (9) 9
cancer research (9) 9
esophagus (9) 9
fluorouracil (9) 9
oxaliplatin (9) 9
solid tumors (9) 9
adenocarcinoma - drug therapy (8) 8
disease-free survival (8) 8
esophageal cancer (8) 8
fluorouracil - administration & dosage (8) 8
hematology, oncology and palliative medicine (8) 8
leucovorin (8) 8
pharmacology/toxicology (8) 8
stomach neoplasms - pathology (8) 8
therapy (8) 8
5-fluorouracil (7) 7
bevacizumab (7) 7
cisplatin - administration & dosage (7) 7
double-blind (7) 7
expression (7) 7
kaplan-meier estimate (7) 7
mutation (7) 7
neoplasm staging (7) 7
oncology, experimental (7) 7
original (7) 7
studies (7) 7
survival rate (7) 7
adenocarcinoma - mortality (6) 6
analysis (6) 6
antibodies, monoclonal - therapeutic use (6) 6
antineoplastic agents - therapeutic use (6) 6
antineoplastic combined chemotherapy protocols - administration & dosage (6) 6
carcinoma (6) 6
drug therapy (6) 6
ligands (6) 6
medical research (6) 6
neutropenia (6) 6
original article (6) 6
oxonic acid - administration & dosage (6) 6
phase-iii (6) 6
platinum (6) 6
stomach neoplasms - mortality (6) 6
tegafur - administration & dosage (6) 6
toxicity (6) 6
1st-line therapy (5) 5
antibodies (5) 5
cancer patients (5) 5
cetuximab (5) 5
colorectal neoplasms - pathology (5) 5
complications and side effects (5) 5
digestive system diseases (5) 5
esophageal neoplasms - drug therapy (5) 5
follow-up studies (5) 5
irinotecan (5) 5
japan (5) 5
leucovorin - administration & dosage (5) 5
medical colleges (5) 5
medicine, experimental (5) 5
metastases (5) 5
monoclonal antibodies (5) 5
monotherapy (5) 5
multicenter (5) 5
oxonic acid - adverse effects (5) 5
pharmacokinetics (5) 5
prognosis (5) 5
retrospective studies (5) 5
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial
by Muro, Kei, Dr and Chung, Hyun Cheol, Prof and Shankaran, Veena, MD and Geva, Ravit, MD and Catenacci, Daniel, MD and Gupta, Shilpa, MD and Eder, Joseph Paul, MD and Golan, Talia, MD and Le, Dung T, MD and Burtness, Barbara, MD and McRee, Autumn J, MD and Lin, Chia-Chi, MD and Pathiraja, Kumudu, MA and Lunceford, Jared, PhD and Emancipator, Kenneth, MD and Juco, Jonathan, MD and Koshiji, Minori, MD and Bang, Yung-Jue, Prof
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 6, pp. 717 - 726
Summary Background Expression of PD-L1 has been shown to be upregulated in some patients with gastric cancer. As part of the phase 1b KEYNOTE-012 study, we... 
Hematology, Oncology and Palliative Medicine | IMMUNITY | ONCOLOGY | ADVANCED MELANOMA | PD-L1 EXPRESSION | ADENOCARCINOMA | B7-H1 | CARCINOMA | T-CELLS | IPILIMUMAB | CLINICAL-SIGNIFICANCE | INFILTRATION | Antibodies, Monoclonal, Humanized - therapeutic use | Prognosis | Follow-Up Studies | Neoplasm Recurrence, Local - metabolism | Humans | Middle Aged | Neoplasm Recurrence, Local - drug therapy | Stomach Neoplasms - metabolism | Male | Stomach Neoplasms - pathology | Survival Rate | Antineoplastic Agents - therapeutic use | Stomach Neoplasms - drug therapy | Adenocarcinoma - drug therapy | Adenocarcinoma - secondary | Neoplasm Recurrence, Local - pathology | B7-H1 Antigen - metabolism | Adenocarcinoma - metabolism | Biomarkers, Tumor - metabolism | Adult | Female | Aged | Neoplasm Staging | Viral antibodies | Medical colleges | Care and treatment | Antibodies | Metastasis | Stomach cancer | Cancer | Analysis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study)
by Muro, Kei, Dr and Boku, Narikazu, MD and Shimada, Yasuhiro, MD and Tsuji, Akihito, MD and Sameshima, Shinichi, MD and Baba, Hideo, Prof and Satoh, Taroh, MD and Denda, Tadamichi, MD and Ina, Kenji, MD and Nishina, Tomohiro, MD and Yamaguchi, Kensei, MD and Takiuchi, Hiroya, Prof and Esaki, Taito, MD and Tokunaga, Shinya, MD and Kuwano, Hiroyuki, Prof and Komatsu, Yoshito, MD and Watanabe, Masahiko, Prof and Hyodo, Ichinosuke, Prof and Morita, Satoshi, Prof and Sugihara, Kenichi, Prof
Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 9, pp. 853 - 860
Summary Background Fluorouracil and folinic acid with either oxaliplatin (FOLFOX) or irinotecan (FOLFIRI) are widely used as first-line or second-line... 
Hematology, Oncology and Palliative Medicine | TRIAL | CAPECITABINE | 1ST-LINE TREATMENT | INFUSIONAL FLUOROURACIL/LEUCOVORIN | THERAPY | ONCOLOGY | 5-FLUOROURACIL/FOLINIC ACID | FLUOROPYRIMIDINES | OXALIPLATIN | III NONINFERIORITY | FAILURE | Prodrugs - administration & dosage | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Colorectal Neoplasms - drug therapy | Adult | Camptothecin - administration & dosage | Female | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Camptothecin - adverse effects | Fluorouracil - analogs & derivatives | Tegafur - adverse effects | Kaplan-Meier Estimate | Oxonic Acid - administration & dosage | Adenocarcinoma - drug therapy | Oxonic Acid - adverse effects | Disease-Free Survival | Prodrugs - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Tegafur - administration & dosage | Aged | Drug Combinations | Adenocarcinoma - mortality | Medical colleges | Chemotherapy | Oncology, Experimental | Colorectal cancer | Leucovorin | Research | Metastasis | Cancer | Fluorouracil | Analysis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial
by Kudo, Toshihiro, PhD and Hamamoto, Yasuo, Dr and Kato, Ken, PhD and Ura, Takashi, MD and Kojima, Takashi, MD and Tsushima, Takahiro, MD and Hironaka, Shuichi, MD and Hara, Hiroki, MD and Satoh, Taroh, Prof and Iwasa, Satoru, PhD and Muro, Kei, MD and Yasui, Hirofumi, MD and Minashi, Keiko, MD and Yamaguchi, Kensei, MD and Ohtsu, Atsushi, PhD and Doki, Yuichiro, Prof and Kitagawa, Yuko, Prof
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 5, pp. 631 - 639
Summary Background Nivolumab is a human monoclonal IgG4 antibody that inhibits programmed cell death protein 1 (PD-1) expressed on activated T cells. We... 
Hematology, Oncology and Palliative Medicine | MONOTHERAPY | ALCOHOL | LIGANDS | ONCOLOGY | SAFETY | SMOKING | CANCER | DOCETAXEL | PD-1 | Hyponatremia - chemically induced | Dyspnea - chemically induced | Lung Diseases - chemically induced | Dehydration - chemically induced | Follow-Up Studies | Lung Diseases - microbiology | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Response Evaluation Criteria in Solid Tumors | Antineoplastic Agents - therapeutic use | Retreatment | Carcinoma, Squamous Cell - drug therapy | Antineoplastic Agents - adverse effects | Aged, 80 and over | Anorexia - chemically induced | Female | Aged | Esophageal Neoplasms - drug therapy | Medical research | Medical colleges | Care and treatment | Chemotherapy | Cell death | Immunoglobulin G | Clinical trials | Medicine, Experimental | T cells | Esophageal cancer | Cancer | Carcinoma | Analysis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial
by Yoshino, Takayuki, Dr and Mizunuma, Nobuyuki, MD and Yamazaki, Kentaro, MD and Nishina, Tomohiro, MD and Komatsu, Yoshito, MD and Baba, Hideo, Prof and Tsuji, Akihito, MD and Yamaguchi, Kensei, MD and Muro, Kei, MD and Sugimoto, Naotoshi, MD and Tsuji, Yasushi, MD and Moriwaki, Toshikazu, MD and Esaki, Taito, MD and Hamada, Chikuma, Prof and Tanase, Takanori, MSc and Ohtsu, Atsushi, MD
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 10, pp. 993 - 1001
Summary Background Treatments that confer survival benefit are needed in patients with heavily pretreated metastatic colorectal cancer. The aim of this trial... 
Hematology, Oncology and Palliative Medicine | CETUXIMAB | INHIBITORS | MUTATIONS | ONCOLOGY | GUIDELINES | Colorectal Neoplasms - mortality | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Double-Blind Method | Colorectal Neoplasms - genetics | Humans | Middle Aged | Uracil - therapeutic use | Male | Proto-Oncogene Proteins - genetics | Trifluridine - therapeutic use | Neoplasm Metastasis | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Adult | Female | Aged | Mutation | Colorectal Neoplasms - pathology | Drug Combinations | Uracil - analogs & derivatives | Care and treatment | Oncology, Experimental | Colorectal cancer | Nucleosides | Clinical trials | Product development | Research | Metastasis | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial
by Yamada, Yasuhide, Dr and Takahari, Daisuke, MD and Matsumoto, Hiroshi, MD and Baba, Hideo, Prof and Nakamura, Masato, MD and Yoshida, Kazuhiro, Prof and Yoshida, Motoki, MD and Iwamoto, Shigeyoshi, MD and Shimada, Ken, MD and Komatsu, Yoshito, MD and Sasaki, Yasutsuna, Prof and Satoh, Taroh, MD and Takahashi, Keiichi, MD and Mishima, Hideyuki, Prof and Muro, Kei, MD and Watanabe, Masahiko, Prof and Sakata, Yuh, MD and Morita, Satoshi, Prof and Shimada, Yasuhiro, MD and Sugihara, Kenichi, Prof
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 13, pp. 1278 - 1286
Summary Background Studies done in Asia have shown that a regimen of S-1 plus oxaliplatin (SOX) has promising efficacy and safety in patients with metastatic... 
Hematology, Oncology and Palliative Medicine | CAPECITABINE | GERCOR | EFFICACY | ONCOLOGY | 1ST-LINE THERAPY | FLUOROPYRIMIDINES | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Bevacizumab | Organoplatinum Compounds - administration & dosage | Antibodies, Monoclonal, Humanized - administration & dosage | Fluorouracil - administration & dosage | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Adult | Female | Chemotherapy, Adjuvant | Drug Administration Schedule | Japan | Kaplan-Meier Estimate | Treatment Outcome | Oxonic Acid - administration & dosage | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Tegafur - administration & dosage | Aged | Infusions, Intravenous | Colorectal Neoplasms - pathology | Neoplasm Staging | Drug Combinations | Medical colleges | Care and treatment | Colorectal cancer | Leucovorin | Metastasis | Antineoplastic agents | Antimitotic agents | Cancer patients | Chemotherapy | Product development | Cross infection | Nosocomial infections | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
by Kang, Won Ki and Kang, Yoon-Koo and Boku, Narikazu and Satoh, Taroh and Ryu, Min-Hee and Chao, Yee and Kato, Ken and Chung, Hyun Cheol and Chen, Jen-Shi and Chen, Li-Tzong and Muro, Kei and Yeh, Kun-Huei and Yoshikawa, Takaki and Oh, Sang Cheul and Oh, Do-Youn and Bai, Li-Yuan and Tamura, Takao and Lee, Keun-Wook and Hamamoto, Yasuo and Kim, Jong Gwang and Chin, Keisho and Minashi, Keiko and Cho, Jae Yong and Tsuda, Masahiro
The Lancet, ISSN 0140-6736, 12/2017, Volume 390, Issue 10111, pp. 2461 - 2471
Patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, two or more previous regimens of chemotherapy have a poor... 
SUPPORTIVE CARE | MEDICINE, GENERAL & INTERNAL | MONOTHERAPY | ADENOCARCINOMA | MISMATCH-REPAIR | OPEN-LABEL | 1ST-LINE THERAPY | COMBINATION | DOCETAXEL | III TRIAL | PLUS | Double-Blind Method | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Antineoplastic Agents - therapeutic use | Stomach Neoplasms - drug therapy | Adenocarcinoma - drug therapy | Esophagogastric Junction | Antineoplastic Agents - adverse effects | Nivolumab | Treatment Failure | Female | Aged | Stomach Neoplasms - mortality | Adenocarcinoma - mortality | Clinical trials | Care and treatment | Chemotherapy | Esophageal cancer | Cancer | Immune checkpoint | Immunotherapy | Ligands | Metastasis | Cancer therapies | Stomach cancer | Esophagus | Tumors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
by Shitara, Kohei and Özgüroğlu, Mustafa and Bang, Yung-Jue and Di Bartolomeo, Maria and Mandalà, Mario and Ryu, Min-Hee and Fornaro, Lorenzo and Olesiński, Tomasz and Caglevic, Christian and Chung, Hyun C and Chung, Hyun Cheol and Muro, Kei and Goekkurt, Eray and Mansoor, Wasat and McDermott, Raymond S and Shacham-Shmueli, Einat and Chen, Xinqun and Chen, Jen-Shi and Mayo, Carlos and Kang, S Peter and Ohtsu, Atsushi and Fuchs, Charles S and Lerzo, Guillermo and O'Connor, Juan Manuel and Mendez, Guillermo Ariel and Lynam, James and Tebbutt, Niall and Wong, Mark and Strickland, Andrew and Karapetis, Chris and Goldstein, David and Vasey, Paul and Van Laethem, Jean-Luc and Van Cutsem, Eric and Berry, Scott and Vincent, Mark and Muller, Bettina and Rey, Felipe and Zambrano, Angela and Guerra, Joaquin and Krogh, Merete and Baeksgaard, Lene and Yilmaz, Mette and Elme, Anneli and Magi, Andrus and Auvinen, Paivi and Alanko, Tuomo and Moehler, Markus and Kunzmann, Volker and Seufferlein, Thomas and Thuss-Patience, Peter and Hoehler, Thomas and Haag, Georg and Al-Batran, Salah-Eddin and Castro, Hugo and Lopez, Karla and Aguilar Vasquez, Mynor and Sandoval, Mario and Lam, Ka On and Cuffe, Sinead and Kelly, Cathy and Geva, Ravit and Hubert, Ayala and Beny, Alex and Brenner, Baruch and Giuseppe, Aprile and Falcone, Alfredo and Maiello, Evaristo and Passalacqua, Rodolfo and Montesarchio, Vincenzo and Hara, Hiroki and Chin, Keisho and Nishina, Tomohiro and Komatsu, Yoshito and Machida, Nozumo and Hironaka, Shuichi and Satoh, Taroh and Tamura, Takao and Sugimoto, Naotaoshi and Cho, Haruhiko and Omuro, Yashushi and Kato, Ken and Goto, Masahiro and Hyodo, Ichinosuke and Yoshida, Kazuhiro and Baba, Hideo and Esaki, Taito and Furuse, Junji and Wan Mohammed, Wan Zamaniah and Hernandez Hernandez, Carlos and Casas Garcia, Juan and Dominguez Andrade, Adriana and Clarke, Katriona and Hjortland, Geir and Glenjen, Nils and Kubiatowski, Tomasz and Jacek, Jassem and Wojtukiewicz, Marek and Lazarev, Sergey and Lancukhay, Yuri and ... and KEYNOTE-061 Investigators and KEYNOTE-061 investigators
The Lancet, ISSN 0140-6736, 07/2018, Volume 392, Issue 10142, pp. 123 - 133
Patients with advanced gastric or gastro-oesophageal junction cancer that progresses on chemotherapy have poor outcomes. We compared pembrolizumab with... 
MISMATCH-REPAIR DEFICIENCY | CELL LUNG-CANCER | MEDICINE, GENERAL & INTERNAL | MULTICENTER | SOLID TUMORS | PD-1 BLOCKADE | ADENOCARCINOMA | DOUBLE-BLIND | NIVOLUMAB | CARCINOMA | Antibodies, Monoclonal, Humanized - adverse effects | Adenocarcinoma - pathology | Antibodies, Monoclonal, Humanized - therapeutic use | Humans | Middle Aged | Esophagogastric Junction - pathology | Paclitaxel - adverse effects | Male | Stomach Neoplasms - pathology | Survival Rate | Treatment Outcome | Stomach Neoplasms - drug therapy | Adenocarcinoma - drug therapy | Paclitaxel - therapeutic use | Esophageal Neoplasms - pathology | Esophageal Neoplasms - mortality | Female | Aged | Infusions, Intravenous | Neoplasm Staging | Esophageal Neoplasms - drug therapy | Adenocarcinoma - mortality | Antimitotic agents | Chemotherapy | Product development | Antineoplastic agents | Esophageal cancer | Cancer | Slopes | Clinical trials | Oncology | Metastasis | Cancer therapies | Stomach cancer | Pembrolizumab | Randomization | Platinum | Paclitaxel | Safety | Growth factors | Cell survival | Survival | Patients | Esophagus | Studies | Medical centres | Interactive systems | Cell death | PD-L1 protein | Response rates | Ligands | Apoptosis | Tumors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Phase II Study of Chemoradiotherapy With 5-Fluorouracil and Cisplatin for Stage II–III Esophageal Squamous Cell Carcinoma: JCOG Trial (JCOG 9906)
by Kato, Ken, M.D and Muro, Kei, M.D and Minashi, Keiko, M.D and Ohtsu, Atsushi, M.D and Ishikura, Satoshi, M.D and Boku, Narikazu, M.D and Takiuchi, Hiroya, M.D and Komatsu, Yoshito, M.D and Miyata, Yoshinori, M.D and Fukuda, Haruhiko, M.D and Gastrointestinal Oncology Study Gr and Japan Clinical Oncology Grp JCOG and Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group (JCOG)
International Journal of Radiation Oncology, Biology, Physics, ISSN 0360-3016, 2011, Volume 81, Issue 3, pp. 684 - 690
Purpose In this Phase II study, we evaluated the efficacy and toxicity of chemoradiotherapy (CRT) with cisplatin (CDDP) and 5-fluorouracil (5-FU) for Stage... 
Radiology | Hematology, Oncology and Palliative Medicine | Esophageal squamous cell carcinoma | Long-term toxicity | Salvage surgery | Chemoradiotherapy | SURGERY | SURVIVAL | THORACIC ESOPHAGUS | CANCER | CHEMOTHERAPY | SALVAGE ESOPHAGECTOMY | RADIATION-THERAPY | ONCOLOGY | CHEMORADIATION | RADIOTHERAPY | DEFINITIVE CHEMORADIOTHERAPY | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | Chemoradiotherapy - adverse effects | Age Factors | Carcinoma, Squamous Cell - pathology | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cisplatin - administration & dosage | Esophageal Neoplasms - pathology | Carcinoma, Squamous Cell - mortality | Fluorouracil - administration & dosage | Esophageal Neoplasms - mortality | Adult | Female | Surveys and Questionnaires | Esophageal Neoplasms - therapy | Radiotherapy Dosage | Chemoradiotherapy - methods | Drug Administration Schedule | Carcinoma, Squamous Cell - therapy | Survival Rate | Remission Induction | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Health Status | Neoplasm Staging | Salvage Therapy - methods | Preoperative Care - methods | Medical colleges | Chemotherapy | Squamous cell carcinoma | Information services | Clinical trials | Esophageal cancer | Information services industry | Cisplatin | Cancer | Fluorouracil | Index Medicus | ESOPHAGUS | DIGESTIVE SYSTEM | COMPLEXES | HETEROCYCLIC COMPOUNDS | DEATH | INFUSION | MEDICINE | AZINES | ANTIMETABOLITES | FLUOROURACILS | IRRADIATION | ORGANIC HALOGEN COMPOUNDS | HYDROXY COMPOUNDS | THERAPY | DRUGS | RADIOLOGY AND NUCLEAR MEDICINE | PNEUMONITIS | ORGANIC NITROGEN COMPOUNDS | COMBINED THERAPY | RADIOLOGY | URACILS | NEOPLASMS | ORGANIC COMPOUNDS | ORGANIC FLUORINE COMPOUNDS | INTAKE | PYRIMIDINES | TOXICITY | SYMPTOMS | TRANSITION ELEMENT COMPLEXES | PLATINUM COMPLEXES | NUCLEAR MEDICINE | ORGANS | SURVIVAL TIME | DISEASES | CARCINOMAS | NAUSEA | BODY
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Nimotuzumab combined with concurrent chemoradiotherapy in Japanese patients with esophageal cancer: A phase I study
by Kato, Ken and Ura, Takashi and Koizumi, Wasaburo and Iwasa, Satoru and Katada, Chikatoshi and Azuma, Mizutomo and Ishikura, Satoshi and Nakao, Yoshinori and Onuma, Hiroshi and Muro, Kei
Cancer Science, ISSN 1347-9032, 03/2018, Volume 109, Issue 3, pp. 785 - 793
Nimotuzumab is a humanized anti‐epidermal growth factor receptor IgG1 monoclonal antibody. This phase I study assessed the tolerability, safety, efficacy, and... 
chemoradiotherapy | esophageal cancer | nimotuzumab | Japanese | epidermal growth factor receptor | FUTURE-DIRECTIONS | CLINICAL-TRIAL | SOLID TUMORS | MONOCLONAL-ANTIBODY | GROWTH-FACTOR RECEPTOR | OVEREXPRESSION | 5-FLUOROURACIL | ONCOLOGY | SQUAMOUS-CELL CARCINOMA | RADIOTHERAPY | III TRIAL | Chemotherapy | Cancer patients | Epidermal growth factor | Immunoglobulin G | Oncology, Experimental | Monoclonal antibodies | Skin | Research | Radiotherapy | Esophageal cancer | Cancer | Appetite | Hyponatremia | Leukopenia | Toxicity | Esophagitis | Radiation therapy | Survival | Cisplatin | Esophagus | Immunogenicity | Lymphopenia | Biomarkers | Pharmacokinetics | Health risk assessment | Neutropenia | Pharmaceuticals | Index Medicus | Original
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild‐type KRAS colorectal cancer‐WJOG 6210G
by Shitara, Kohei and Yonesaka, Kimio and Denda, Tadamichi and Yamazaki, Kentaro and Moriwaki, Toshikazu and Tsuda, Masahiro and Takano, Toshimi and Okuda, Hiroyuki and Nishina, Tomohiro and Sakai, Kazuko and Nishio, Kazuto and Tokunaga, Shoji and Yamanaka, Takeharu and Boku, Narikazu and Hyodo, Ichinosuke and Muro, Kei
Cancer Science, ISSN 1347-9032, 12/2016, Volume 107, Issue 12, pp. 1843 - 1850
This randomized phase II trial compared panitumumab plus fluorouracil, leucovorin, and irinotecan (FOLFIRI) with bevacizumab plus FOLFIRI as second‐line... 
colorectal cancer | RAS mutation | panitumumab | liquid biopsy | Bevacizumab | 1ST-LINE TREATMENT | LEUCOVORIN | MULTICENTER | DETERMINANTS | PHASE-III | ACQUIRED-RESISTANCE | FLUOROURACIL | TRIAL | CETUXIMAB | ONCOLOGY | 2ND-LINE TREATMENT | ras Proteins - genetics | Colorectal Neoplasms - genetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Biomarkers, Tumor | Fluorouracil - therapeutic use | Neoplasm Metastasis | Leucovorin - adverse effects | Fluorouracil - adverse effects | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Adult | Female | Leucovorin - therapeutic use | Proto-Oncogene Proteins B-raf | Camptothecin - analogs & derivatives | Camptothecin - adverse effects | Bevacizumab - administration & dosage | Camptothecin - therapeutic use | Kaplan-Meier Estimate | Treatment Outcome | Retreatment | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Alleles | Aged | Mutation | Antimitotic agents | Chemotherapy | Endothelial growth factors | Analysis | Oncology, Experimental | Colorectal cancer | Clinical trials | Metastasis | Research | Antineoplastic agents | Blood proteins | Cancer | Immunoassay | Colorectal carcinoma | Values | Oncology | Serum proteins | Cancer therapies | K-Ras protein | Metastases | Proteins | Oxaliplatin | Epidermal growth factor | Vascular endothelial growth factor | Deoxyribonucleic acid--DNA | Immunoglobulins | Survival | Patients | Studies | Irinotecan | Biomarkers | Ligands | Original
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Phase I/II trial of chemoradiotherapy with concurrent S‐1 and cisplatin for clinical stage II/III esophageal carcinoma (JCOG 0604)
by Tahara, Makoto and Fuse, Nozomu and Mizusawa, Junki and Sato, Akihiro and Nihei, Keiji and Kanato, Keisuke and Kato, Ken and Yamazaki, Kentaro and Muro, Kei and Takaishi, Hiromasa and Boku, Narikazu and Ohtsu, Atsushi
Cancer Science, ISSN 1347-9032, 10/2015, Volume 106, Issue 10, pp. 1414 - 1420
We carried out a phase I/II trial of chemoradiotherapy concurrent with S‐1 and cisplatin to determine the maximum tolerated dose and recommended dose and to... 
S‐1 | stage II/III | cisplatin | esophageal carcinoma | Chemoradiotherapy | Esophageal carcinoma | Stage II/III | S-1 |